E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Respiratory distress secondary to SARS-Cov-2 infection |
Distrés respiratorio secundario a infección por SARS-Cov-2. |
|
E.1.1.1 | Medical condition in easily understood language |
Respiratory distress secondary to SARS-Cov-2 infection |
Distrés respiratorio secundario a infección por SARS-Cov-2 |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this project is to evaluate the efficacy of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19. |
El objetivo principal de este proyecto es evaluar la eficacia de la administración de células troncales mesenquimales derivadas de tejido adiposo y expandidas, en pacientes infectados por SARS-Cov-2 con complicaciones tipo COVID-19. |
|
E.2.2 | Secondary objectives of the trial |
-To evaluate the safety of the administration of expanded allogeneic adipose tissue mesenchymal stem cells, in patients infected with SARS-COV-2 with complications like COVID-19. -To evaluate preclincial variables |
-Evaluar la seguridad de la administración de células troncales mesenquimales derivadas de tejido adiposo y expandaidas, en pacientes infectados por SARS-CoV-2 con complicaciones tipo COVID. -Evaluar variables preclínicas |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Patients of both sexes. -Over 18 years. -Confirmation of SARS-COV-2 infection by RT-PCR in respiratory sample. -Respiratory failure requiring intubation and connection to mechanical ventilation, secondary to SARS-CoV-2 infection. -Criteria for acute respiratory distress: acute bilateral alveolar-interstitial infiltrate not compatible with left ventricular failure (demonstrated with ultrasound or hemodynamic parameters), sudden onset, and blood gas compromise with a PaO2 / FiO2 ratio <200 mm-Hg. -Women of childbearing potential should have a negative urine pregnancy test performed at the time of study enrollment. -Written or verbal informed consent from the patient or the legal representative. |
-Pacientes de ambos sexos -Mayores de 18 años -Confirmación de infección por SARS-COV-2 mediante RT-PCR en una muestra respiratoria -Fallo respiratorio que requiera intubación y conexión a ventilación mecánica, secundario a infección por SARS-Cov-2. -Criterios de distrés respiratorio agudo: infiltrado agudo alveolo-intersticial no compatible con fallo de ventrículo izquierdo (demostrado con ecografía y parámetros hemodinámicos), de inicio súbito, y compromiso gaseoso con ratio PaO2/FiO2<200 mmHg. -Mujeres en edad fértil deben tener prueba de embarazo en orina negativa realizada en el momento de inclusión en el estudio. -Consentimiento informado escrito o verbal por parte del paciente o del representante legal. |
|
E.4 | Principal exclusion criteria |
-Any other cause of acute respiratory distress not attributable to SARS-Cov-2. -RT-PCR of SARS-Cov-2 negative. Mult Multi-organ failure (more than three organs) -Severe respiratory failure requiring extracorporeal support (ECMO) -Moderate- severe COPD requiring chronic home oxygen therapy. -Pregnancy, lactation and women of childbearing age but who do not take effective contraceptive measures. -Active tumor disease. -Previous immunosuppressive treatment. -Allergy or hypersensitivity to the administered products. -History of deep vein thrombosis or pulmonary embolism in the last 3 years. -Participation in other clinical trials during the 3 months prior to the initial visit. |
-Cualquier otra causa de distrés respiratorio agudo que no sea atribuible a SARS-Cov-2. -RT-PCR para SARS-Cov-2 negativa. -Fallo multiorgánico (más de 3 órganos). -Fallo respiratorio severo que requiera soporte extracorpóreo (ECMO). -EPOC moderado-severo que requiera oxigenoterapia crónica domiciliaria. -Embarazo, lactancia, o mujeres que no edad fértil que no tomen medidas contraconceptivas eficaces. -Enfermedad tumoral activa. -Tratamiento inmunosupresor previo. -Alergia o hipersensibilidad a los productos administrados. -Historia de trombosis venosa o pulmonar en los últimos 3 años. -Participación en otros ensayos clínicos durante los 3 meses previos a la visita de inicio. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
% survival at 28 days after treatment Days from the patient enters the study until the temperature normalizes: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. o Normalization of the temperature defined as: reaching a body temperature between 35ºC and 37ºC Days until patient was extuted: defined as (Total days with mechanical ventilation) - (Total days without mechanical ventilation) Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. Number of patients who abandoned mechanical ventilation, defined as: (Total of patients with mechanical ventilation at the time of inclusion) - (Total of patients who abandoned mechanical ventilation) Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. Number of patients that go from Mechanical Ventilation to oxygen therapy: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. Duration of oxygen therapy (days), defined as: (Total days in the study) - (Total days of need for oxygen therapy). Measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. Days of stay in the Intensive Care Unit: defined as (Total days in the study) - (Total days in the Intensive Care Unit). Duration of hospitalization (days): defined as (Total days in the study) - (Total days hospitalized) Oxygen saturation: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month Pa PaO2 / FiO2 ratio: measurement on Day 1, Day 3, Day 7, Day 10, 3rd month, and 6th month. Radi Radiological pattern on Chest Radiography: decrease in interstitial alveolar infiltrates: yes / no. Measurement on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. FA SOFA score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month. Murray score: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month Analytical parameters: measured on Day 1, Day 3, Day 7, Day 10, 3rd month and 6th month o Hties, Hb, Hto, VCM, Leukocytes with leukocyte formula, platelets. procalcitonin o Glucose, Glycosylated Hb, urea, uric acid, creatinine, total bilirubin, direct bilirubin, sodium, potassium, calcium, chlorine, total protein, C-reactive protein, AST, ALT, GGT, Cl Cr and FG. o Coagulation: prothrombin time (TP), activated partial thromboplastin time (APTT), thrombin time (TT), Fibrinogen, INR. o IL-6, IL-2, DD, lactate dehydrogenase, CK (Creatin Kinase), Alkaline Phosphatase o Lymphocyte population: CD4 +, CD8 + T lymphocytes, B lymphocytes, NK cells or C3, C4, IgG, IgA, IgM.
|
% de supervivencia a los 28 días posteriores al tratamiento Días desde que el paciente entra en el estudio hasta que se normaliza la temperatura: medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. o Normalización de la temperatura definida como: alcanzar una temperatura corporal entre 35ºC y 37ºC Días hasta que se extuba el paciente: definido como (Total de días con ventilación mecánica) – (Total de días libre de ventilación mecánica)Medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. Número de pacientes que abandona la ventilación mecánica, definido como: (Total de pacientes con ventilación mecánica en el momento de la inclusión) – (Total de pacientes que abandona la ventilación mecánica) Medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. Número de pacientes que pasan de Ventilación Mecánica a oxigenoterapia: medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. Duración de la oxigenoterapia (días), definido como: (Total de días en el estudio)-(Total de días de necesidad de oxigenoterapia). Medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. Días de estancia en la Unidad de Cuidados Intensivos: definido como (Total de días en el estudio) – (Total de días en la Unidad de Cuidados Intensivos). Duración de la hospitalización (días): definido como (Total de días en el estudio) – (Total de días hospitalizado) Saturación de oxígeno: medición en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes Ratio PaO2/FiO2: medición en Día 1, Día 3, Día 7, Día 10, 3º mes, y 6º mes. Patrón radiológico en Radiografía de Tórax: disminución de infiltrados alveolo intersticiales: sí/no. Medición en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. SOFA score: medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes. Murray score: medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes Parámetros analíticos: medido en Día 1, Día 3, Día 7, Día 10, 3º mes y 6º mes o Hties, Hb, Hto, VCM, Leucocitos con fórmula leucocitaria, plaquetas. procalcitonina o Glucosa, Hb Glicosilada, urea, ácido úrico, creatinina, bilirrubina total, bilirrubina directa, sodio, potasio, calcio, cloro, proteínas totales, proteína C reactiva, AST, ALT, GGT, Cl Cr y FG. o Coagulación: tiempo de protrombina (TP), tiempo de tromboplastina parcial activada (TTPA), tiempo de trombina (TT), Fibrinógeno, INR. o IL-6, IL-2, DD, lactato deshidrogenasa, CK (Creatin Kinasa), Fosfatasa Alcalina o Población linfocitaria: linfocitos T CD4+, CD8+, Linfocitos B, Células NK o C3, C4, IgG, IgA, IgM.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Day 1, Day 3, Day 7, day 10, Third Month, Sixth Month |
Día 1, Día 3, Día 7, Día 10, Tercer mes, Sexto mes. |
|
E.5.2 | Secondary end point(s) |
Preclinical variables Immune functions o T lymphocyte count o Count of CD4 + T lymphocytes, CD8 + T lymphocytes and B lymphocytes (flow cytometry) o Alanine aminotransferase Analytics o Blood concentration of IL-1β, IL-2R, IL-4 IL-6, IL-8, IL-10, TNF-α, IFNγ, TGFβ o Pro-Peptide B natriuretic (pro-BNP)
Safety variables % and type of complications derived from treatment. o Complications during the application of the treatment (Day 1) o Complications on Day 3, Day 7, Day 10, Day 28, 3rd month and 6th month. |
Variables preclínicas Funciones inmunológicas o Contaje de linfocitos T o Contaje de linfocitos T CD4+ , linfocitos T CD8+ y linfocitos B (citometría de flujo) o Alanino aminotranferasa Analítica o Concentración en sangre de IL-1β, IL-2R, IL-4 IL-6, IL-8,IL-10,TNF-α, IFNγ, TGFβ o Pro-Péptido B natriurético (pro-BNP)
Variables de seguridad % y tipo de complicaciones derivadas del tratamiento. o Complicaciones durante la aplicación del tratamiento (Día 1) o Complicaciones en el Día 3, Día 7, Día 10, Día 28, 3º mes y 6º mes.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Day 1, Day 3, Day 7, Day 10, Third Month, Sixth Month |
Día 1, Día 3, Día 7, Día 10, Tercer Mes, Sexto Mes |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | Yes |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last patient last visit |
último paciente última visita |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |